ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
… medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNAediting technology development. This platform technology …
… Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and change lives. A team of 180+ … of the communities we serve. Our proprietary Axiomer™ RNAediting technology platform enables the editing of …
… Massachusetts, USA. At ProQR, we are on a mission to edit RNA, treat disease and change lives. A team of 180+ … of the communities we serve. Our proprietary Axiomer™ RNAediting technology platform enables the editing of …
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
